【摘要】 目的评价晚期鼻咽癌(NPC)患者应用尼妥珠单抗联合紫杉醇脂质体、顺铂治疗方案的临床疗效及安全性。方法对16例晚期NPC患者采用尼妥珠单抗联合紫杉醇脂质体、顺铂方案治疗:尼妥珠单抗200mg,每周1次,连用6个周期,之后同剂量每2周1次进行巩固治疗,至病情进展停用;紫杉醇脂质体175mg/m2静脉滴注;顺铂(DDP)75mg/m2静脉滴注,分3d用,21d为1个周期。治疗后观察其疗效及不良反应。结果 16例患者中完全缓解3例(18.75%),部分缓解12例(75.00%),疾病稳定1例(6.25%),进展0例,总有效率(RR)为93.75%。1年总生存率(OS)为93.75%,1年无瘤生存率(DFS)为87.50%。主要不良反应为骨髓抑制、胃肠道反应和关节肌肉疼痛,Ⅲ～Ⅳ度白细胞减少发生率为18.75%,无严重并发症发生。结论尼妥珠单抗联合紫杉醇脂质体、顺铂辅治晚期NPC有较好的疗效,且不良反应少,值得推广应用。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of nimotuzumab combined with paclitaxel liposome and cisplatin in advanced nasopharyngeal carcinoma.Methods 16 cases patients with advanced nasopharyngeal carcinoma were treated with nimotuzumab combined with paclitaxel liposome and cisplatin:Nimotuzumab 200mg,once a week for six weeks,after the same dose,for consolidation therapy,2 weeks one time progression to the disabled;Paclitaxel liposome 175mg/m2 intravenous dripping;Cisplatin 75mg/m2 intravenous dripping,21d was a treatment period.After treatment,observed effect and adverse reaction.Results 16 cases patients in the complete remission 3 cases(18.75%),partial remission 12 cases(75.00%),stable disease 1 case(6.25%),progress 0 case,the total effective rate(RR) was 93.75%.1-year overall survival(OS) was 93.75%,1-year disease-free survival(DFS) was 87.50%.The major adverse reaction was myelosuppression,gastrointestinal reactions and joint and muscle pain,the incidence of Ⅲ～Ⅳ neutropenia was 18.75%,without serious complications.Conclusion Nimotuzumab combined with paclitaxel liposome and cisplatin is a effective regimen for patients with advanced nasopharyngeal carcinoma,and the adverse reaction less.更多还原